UA79674C2 - Triazol compounds suitable for use in therapeutics - Google Patents

Triazol compounds suitable for use in therapeutics Download PDF

Info

Publication number
UA79674C2
UA79674C2 UAA200508142A UA2005008142A UA79674C2 UA 79674 C2 UA79674 C2 UA 79674C2 UA A200508142 A UAA200508142 A UA A200508142A UA 2005008142 A UA2005008142 A UA 2005008142A UA 79674 C2 UA79674 C2 UA 79674C2
Authority
UA
Ukraine
Prior art keywords
compound
chloro
tetrahydro
formula
dichloromethane
Prior art date
Application number
UAA200508142A
Other languages
English (en)
Ukrainian (uk)
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Thomas Ryckmans
Alan Stobie
Rachel Jane Russell
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/000432 external-priority patent/WO2004074291A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of UA79674C2 publication Critical patent/UA79674C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
UAA200508142A 2003-07-23 2004-09-02 Triazol compounds suitable for use in therapeutics UA79674C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction
PCT/IB2004/000432 WO2004074291A1 (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
UA79674C2 true UA79674C2 (en) 2007-07-10

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200508142A UA79674C2 (en) 2003-07-23 2004-09-02 Triazol compounds suitable for use in therapeutics

Country Status (12)

Country Link
EP (1) EP1656183B1 (ja)
JP (1) JP2006528171A (ja)
AT (1) ATE380048T1 (ja)
BR (1) BRPI0412255A (ja)
CA (1) CA2533177A1 (ja)
CL (1) CL2004001702A1 (ja)
GB (1) GB0317227D0 (ja)
MX (1) MXPA05014200A (ja)
TW (1) TW200510424A (ja)
UA (1) UA79674C2 (ja)
WO (1) WO2005006899A1 (ja)
ZA (1) ZA200505957B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CA2533177A1 (en) 2005-01-27
CL2004001702A1 (es) 2005-05-13
ZA200505957B (en) 2006-11-29
EP1656183A1 (en) 2006-05-17
WO2005006899A1 (en) 2005-01-27
GB0317227D0 (en) 2003-08-27
MXPA05014200A (es) 2006-07-03
JP2006528171A (ja) 2006-12-14
BRPI0412255A (pt) 2006-09-19
EP1656183B1 (en) 2007-12-05
ATE380048T1 (de) 2007-12-15
TW200510424A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
EP3215509B1 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN106029076B (zh) 作为bet溴域抑制剂的苯并哌嗪组合物
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
CN103221402B (zh) 三唑衍生物及其用于神经障碍的用途
UA122433C2 (uk) Заміщена піперидинова сполука та її застосування
JP4748320B2 (ja) 環状アミン誘導体又はその塩
TW201910328A (zh) 雜環化合物
TW201031407A (en) Novel compounds
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
WO2006021882A1 (en) Triazolobenzodiazepines and their use as vasopressin antagonists
CN101981031A (zh) 具有促肾上腺皮质激素释放因子拮抗活性的三环化合物和含有它们的药物组合物
CN108289893B (zh) 人类血浆激肽释放酶抑制剂
CN102947310A (zh) 作为5-ht2a和d3受体的双重调节剂的稠合吡啶化合物
WO2019228404A1 (zh) 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
TW202128642A (zh) 用於疾病治療之雙白胺酸拉鍊(dlk)激酶的雙環[1.1.1]戊烷抑制劑
CN102666526A (zh) 作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物
JPH09512528A (ja) バソプレッシン拮抗物質としてのベンズアミド誘導体
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
WO2020038387A1 (zh) 高活性sting蛋白激动剂
CN108883122A (zh) 有用于治疗疾病的c-糖苷化合物
HRP20050681A2 (en) Triazole compounds useful in therapy
JP2022097655A (ja) 非ペプチドオキシトシン受容体アゴニスト
TWI826492B (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
JPH08508039A (ja) 選択的コレシストキニン−b受容体拮抗薬としてのテトラヒドロ−1h−ベンゾアゼピノンおよびヘキサヒドロアゼピノン
TW202138352A (zh) 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法